ASP6981 + Placebo
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Jan 22, 2018 โ May 30, 2018
NCT ID
NCT03356639About ASP6981 + Placebo
ASP6981 + Placebo is a phase 1 stage product being developed by Astellas Pharma for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT03356639. Target conditions include Schizophrenia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03356639 | Phase 1 | Completed |
Competing Products
20 competing products in Schizophrenia